((自动化翻译由路透提供，请见免责声明 ))
路透10月8日 - 丹麦的西兰制药公司 周二称，美国食品和药物管理局(FDA)，已就其预防和治疗遗传性疾病患儿低血糖的药物发出了完全回复函$(CRL)$。
西兰正在寻求FDA批准达西胰高血糖素，该药计划用于7天或7天以上的先天性高胰岛素血症患者$(CHI)$，这是一种遗传性疾病，患者的胰腺会分泌过多的胰岛素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.